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A B S T R A C T
Purpose: Several studies suggest that vagal nerve stimulation (VNS) is an effective treatment for
medication-resistant epileptic patients, although patients’ medication was usually modiﬁed during the
assessment period. The purpose of this prospective study was to evaluate the long-term effects of VNS, at
18 months of follow-up, on epileptic patients who have been on unchanged antiepileptic medication.
Methods: Forty-three patients underwent a complete epilepsy preoperative evaluation protocol, and
were selected for VNS implantation. After surgery, patients were evaluated on a monthly basis,
increasing stimulation 0.25 mA at each visit, up to 2.5 mA. Medication was unchanged for at least 18
months since the stimulation was started. The outcome was analysed in relation to patients’ clinical
features, stimulation parameters, epilepsy type, magnetic resonance imaging (MRI) results, and history
of prior brain surgery.
Results: Of the 43 operated patients, 63% had a similar or greater than 50% reduction in their seizure
frequency. Differences in the responder rate according to stimulation intensity, age at onset of epilepsy,
duration of epilepsy before surgery, previous epilepsy surgery and seizure type, did not reach statistical
signiﬁcance. Most side effects were well tolerated.
Conclusions: 62.8% of our series of 43 medication-resistant epileptic patients experienced a signiﬁcant
long-term seizure reduction after VNS, even in a situation of on unchanged medical therapy. Patient
characteristics predictive of VNS responsiveness remain subject to investigation. Controlled studies with
larger sample sizes, on VNS for patients with medication-resistant epilepsy on unchanged medication,
are necessary to conﬁrm VNS efﬁcacy for drug-resistant epilepsy, and to identify predictive factors.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Several studies have suggested that vagal nerve stimulation
(VNS) is an effective therapy for reducing seizure frequency in
medication resistant epileptic patients, who are poor candidates
for resection or in those in whom resection has failed.2,4,5,8–
10,12,13,29 In previous published series, VNS achieved a 50% greater
seizure frequency reduction in 50–60% of implanted patients after
1 year of therapy.18,19,25 In those studies, concomitant changes in
antiepileptic drugs were allowed.3,4,13,22,23,37,51 A progressive
decline in seizure frequency is usually found during the ﬁrst year
of stimulation, and it remains uncertain if the progressive
improvement seen with longer VNS exposures might be ascribable
to a modiﬁcation in the medical therapy, rather than to sustained* Corresponding author at: Division of Neurosurgery, University Hospital La
Princesa, C/Diego de Leo´n 32, 28006 Madrid, Spain. Tel.: +34 915202200/17430;
fax: +34 914013582.
E-mail address: cristinatorresdiaz@yahoo.es (C.V. Torres).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.09.008VNS.14,16,17,30 To date, there is only one study performed in the
adult population on unchanged medical therapy during the
postoperative evaluation.30 In this study, the patients’ outcome
was assessed 1 year after surgery. It has been reported that no
speciﬁc antiepileptic drugs seem to have additive antiseizure
effects with VNS; however, to precisely evaluate the net impact of
vagal stimulation in operated patients, it is essential to maintain
stable doses of the administered drugs. The purpose of this study
was to prospectively evaluate the long-term effects of VNS, at 18
months of follow-up, on epileptic patients who have been on
unchanged antiepileptic medication.
2. Materials and methods
Forty-three adult patients with medication-resistant epilepsy
were treated with VNS in our institution, from 2005 to 2009.
Preoperatively, all patients had undergone a complete preopera-
tive epilepsy evaluation protocol,39,47 which includes videoelec-
troencephalogram (VEEG), 1.5 T magnetic resonance imaging
(MRI), interictal single-photon emission computed tomographyvier Ltd. All rights reserved.
Table 2
Differences between types of patients undergoing vagal nerve stimulation at our
institution, at 2 years from surgery.
Patients’ features Responders Non-responders
Mean seizure frequency
reduction
69.8% (18.1) 4.3% (13.6)
Mean age at surgery 33 (10.5) years 34 (14.16) years
Mean age at the
epilepsy onset
6.9 (5.8) years 12.8  13.8 years
Mean duration of
epilepsy before surgery
26  9.6 years 21, 8.8 years
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ment. Findings of the presurgical evaluation were discussed at a
multidisciplinary case conference, where decisions were made
about the possibility and type of brain surgery, as well as VNS, or
the need for further investigations.
The implanted system was the 1Cyberonics VNS TherapyTM,
and the surgical technique has been previously described23,37; all
of the implantations were performed by the same surgeon. Chronic
stimulation was activated 15 days after the surgery. The initial
parameters were: 0.25 mA; 20 Hz, 250 ms, 30 s stimulus on-time
and 5 min stimulus off-time. Patients were evaluated on a monthly
basis, increasing stimulation by 0.25 mA at each visit up to 2.5 mA,
if there were no major adverse effects (except for one case, in
whom the stimulation was set at 2.75 mA). When patients reached
this level of stimulation, they were reviewed every 6 months,
except for those that needed more frequent follow-ups due to
medical reasons.
In the postoperative visits, seizure frequency, side effects, and
other signiﬁcant information reported by family members and
caregivers, was collected. Seizures were classiﬁed, according to
their frequency, as daily seizures if the patient had 7 or more per
week, as weekly seizures if the patient had from 1 to 6 a week, and
as monthly seizures if the patient had less than four per month.
Responders were deﬁned as having a 50% or greater reduction in
seizure frequency with respect to the mean seizure frequency
during the last year before the implantation of VNS. Changes in the
pharmacological treatment were not allowed during the ﬁrst 18
months of postoperative follow-up.
Group mean differences in percentage of reductions in seizure
frequency were tested non-parametrically if variables were not
distributed normally, and using the paired Student’s t-test for
normal distributions. Normality was evaluated using the Kolmo-
gorov–Smirnov test. The software SPSS 17.0 was used for statistical
analysis. The signiﬁcance level was set at p = 0.05. Results are
shown as the mean  SEM, except where otherwise indicated. This
study was approved by the local ethics committee board.
3. Results
Clinical characteristics of the patients are shown in Table 1. The
study involved 22 women and 21 men. The mean age at epilepsy
onset was 9 (9.9) years, and the mean age at implantation was 34
(11.8) years. The majority of patients had daily multifocal or
generalised seizures (51%), and 12 patients had undergone a previous
surgery for epilepsy, which proved unsuccessful.
The mean seizure frequency reduction at 18 months follow-up
was 46.6% (35.5) (Table 2). Twenty-seven of the 43 patientsTable 1
Patient demographics.
Epilepsy type (n)
Generalised or multifocal epilepsy 22
Temporal lobe epilepsy 5
Frontal lobe epilepsy 13
Other extratemporal locations 3
Baseline seizure rate (mean)
Daily seizures (n) 34
Weekly seizures (n) 5
Monthly seizures (n) 4
Patients with previous epilepsy surgery (n) 12
Temporal resection 2
Extratemporal resection 7
Subpial transection 1
Callosotomy 2
Duration of epilepsy before surgery (mean years) 25 years (9.6)included in the analysis (63%) were responders. Among the 27
responders, seven patients (16% of the total sample), had a greater
than 90% seizure frequency reduction. Four of these 7 patients with
90% of seizure reduction had frontal seizures (one of them was
seizure-free), one patient had occipital-temporal seizures, and 2
patients had generalised seizures. Clinical features of responders and
non-responders are summarised in Table 2.
Patients and caregivers reported other positive aspects derived
from VNS: Ten patients referred to a reduction in seizure duration
and severity; three patients reported a disappearance of the
generalised tonic–clonic seizures, with persistence of the other
seizure types; ten patients with mental retardation showed an
improvement in alertness; and one patient experienced a non-
quantiﬁed weight loss. One patient, however, reported an increase
in the duration and intensity of his seizures.
Twenty-two patients experienced side-effects. The most
common were mild, consisting in hoarseness, neck tingling or
occasional coughing at the time when the signal was on, all of
which were usually well tolerated. Two patients had intermittent
dyspnoea, and another patient experienced occasional episodes of
dysphagia with stimulation. Irritability was reported by two
families, in the context of a general improvement in the level of
alertness. Five had severe side effects, requiring their VNS
generators to be inactivated or explanted. Three of the 5 patients
that stopped receiving stimulation had been responders. Reasons
for explantation were infection in two patients, and odynophagia,
in one patient. One patient had an exacerbation of a previous
behaviour disturbance, with severe aggressiveness, which im-
proved when the stimulator was inactivated. Seizure reduction
was maintained after the stimulation was stopped. Another
stimulator was removed at family request, owing to a persistent
abdominal pain.
For the 38 patients that continued receiving stimulation,
intensity ﬂuctuated between 0.5 mA and 2.75 mA. Mean seizureFig. 1. Seizure reduction rate by stimulation intensity, in our series of patients on
unchanged medication undergoing vagal nerve stimulation for medication-
resistant epilepsy, at the second year follow-up. mA, miliamperes.
Fig. 2. Seizure frequency reduction rate by type of epilepsy, in our cohort of patients
treated with vagal nerve stimulation for medication-resistant epilepsy, on
unchanged medication, at the second year follow-up.
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Fig. 1. Two patients receiving stimulation at 0.25 mA, obtained a
greater than 90% reduction in the frequency of their seizures. The
responder rate for patients at 2 mA was 71% (17 out of 24
patients, whereas it was 53% for those at <2 mA (7 out of 19
patients).
The relationship between the clinical outcome and the intensity
of stimulation, epilepsy type and location, and frequency did not
reach statistical signiﬁcance. Patients with generalised epilepsy
had a mean seizure frequency reduction of 49.4  34.8%, and those
with focal epilepsy, 44.5  35.6%. Among them, patients with
temporal epilepsy had a seizure reduction rate of 63.0  34.8%
(Fig. 2). We analysed the percentage of responders by epilepsy
location, and we found that 4 out of 5 (80%) of the patients with
temporal lobe epilepsy, 15 out of 22 (74%) of the patients with
generalised epilepsy, 6 out of 13 (46%) of the patients with frontal
epilepsy, and 1 out of 3 (33%) of those with other extratemporal
seizures, were responders.
Twenty-three out of 34 (67%) patients with daily seizures
responded to stimulation, whereas those with monthly or 5 weekly
seizures had a responder rate of 50% (2 out of 5, and 2 out of 4
patients, respectively). Eight out of 12 (66%) patients with a history
of previous epilepsy surgery were responders, while of those
without a previous operation, 10 out of 21 (50%) responded to
stimulation.
4. Discussion
Given the complexity and degree of disability of patients
treated with VNS, most of the studies have allowed modiﬁcation of
the patients’ antiepileptic medication types and doses after the
implantation32,33; this may signiﬁcantly affect the analysis of the
results.36,41,44–46,48,49 To our knowledge, this is the only long-term
prospective study that has been performed on VNS for adults with
no changes in the medical treatment during the follow-up (6).
In our series, the percentage of epileptic patients that achieved
a 50% or greater seizure frequency reduction, 18 months after VNS
implantation, was 63%, and the mean reduction in seizure
frequency was 46.6%. In various published series, an equal or
higher than 50% reduction in seizure frequency was achieved in
about 50% of patients (18.4–67%), and the mean reduction in the
frequency of seizures was 42.8% (range 28–66%).7,15,21,35,43,53 Inthe only study to date, performed on an adult population where
medication type and doses were held totally constant during the
postoperative period, the median reduction in seizure frequency, 1
year after the stimulation was started, was 63%.30
The implantation of VNS implies frequent visits to clinic and
therefore the possibility of a more careful adjustment of medical
therapy; moreover, patients might derive an improvement in
seizure frequency from the administration of new drugs. On the
other hand, our results are similar to those obtained in
institutions with extensive experience in epilepsy and vagal
stimulation, suggesting that changes in medication therapy
during the period of adjustment of parameters do not appear to
beneﬁt patients.30 The absence of medication changes, which
can interfere with the evaluation of seizure frequency and side
effects, may be helpful in optimising stimulation settings and
thus, in improving response rates. Moreover, as most neurolo-
gists and patients hope to decrease the number of medications
after VNS placement, it is possible that a reduction in the
medication regime might have had a detrimental effect on
patients undergoing VNS.
There are several studies suggesting that high intensity of
stimulation corresponds to better outcome, although some other
authors consider the time of exposure to the treatment, and not the
intensity of stimulation, the key factor that leads to appropriate
responses.15,18,26,30,40 In our series, the relationship between the
clinical outcome and the intensity of stimulation was indepen-
dently analysed for the duration of stimulation, since the outcome
was uniformly considered at 18 months. Outcome differences
according to intensity of stimulation were not statistically
signiﬁcant, and there were also some very satisfactory results
besides the usual therapeutic values of stimulation.31,34 Other than
frontal focal epilepsy and younger age at the VNS implantation,
have also been considered positive predictive factors for VNS
response in various studies,26,30 although no deﬁnite conclusions
have been drawn.23,26–28 In our series, 15 out of 22 patients with
generalised epilepsy were responders, and 4 of the 7 patients that
obtained a frequency reduction of more than 90% had frontal
epilepsy. It is also of note that our patients’ mean epilepsy duration
at the time of surgery (25 years), was very high.30,42 Finally, the
existence of a previous surgery has been suggested as a negative
predictive factor after VNS.4 It is of importance to conﬁrm these
results, because they might substantially modify VNS patient
selection. In our series, 8 out of 12 patients with a previous surgery
attained satisfactory results from stimulation. Further studies on
VNS for epileptic patients on unchanged medication are needed to
elucidate which are the main predictive factors of responsiveness
to VNS.
The impact of the VNS in other domains of interest has been
documented in several studies.20,42,43 The improvement in mood
and cognitive performance has led to indicate VNS for patients
with chronic depression, although later results have been
conﬂicting.42,43 In our series, a positive effect on alertness has
been observed in almost a quarter of the patients. Reduction in
seizure frequency and independent mechanisms for regulation of
various centroencephalic nuclei have been implicated in these
processes, although they have not been yet elucidated.23,42,43,50 It
must be said that, occasionally, the improvement of the level
of alertness has not been linked to an improvement in the
quality of life, since patients are more aware of the limitations of
their illness. In our series, previous behaviour disorders were
exacerbated.1,6,22,23,52,54
There are limitations to our study, since a control group was not
included in the analysis. It is difﬁcult to compare previously
reported series of patients with drug-resistant epilepsy under the
best medical treatment with our series because of differences
in the deﬁnition of drug-resistant epilepsy and patient
E. Garcı´a-Navarrete et al. / Seizure 22 (2013) 9–1312characteristics.11,55–58 In previous reports, the remission rate for
epileptic patients that have been resistant to at least two
antiepileptic drugs oscillates between 4 and 5% per year, and
around 50% of patients might be responders in the long
term.11,24,38,54,55 VNS, as any chronic implanted medical device,
requires unambiguous positive evidence for therapeutic superior-
ity over conservative treatment in regards to costs, risks, and
adverse effects. Despite the fact that our study eliminates the
confounding factor of medication changes during the assessment
period after VNS implantation, there is a need for long-term
controlled prospective studies with patients under VNS, and
without changes in medication, to conﬁrm our results.
5. Conclusions
62.8% of our series of 43 medication-resistant epileptic patients
experienced a signiﬁcant long-term seizure reduction after VNS,
even in a situation of unchanged medical therapy. Patient
characteristics predictive of VNS responsiveness remain subject
to investigation. It is necessary to perform controlled studies with a
larger number of subjects on unchanged antiepileptic medication
to draw deﬁnitive conclusions
Financial disclosure
The authors have not had any ﬁnancial support in conjunction
with the generation of this submission.
Acknowledgments
This work was partially supported by a Grant from the Plan
Nacional de Investigacion Cientﬁca, Desarrollo e Innovacion Tecnol
ogica (I+D+I), Instituto de Salud Carlos III, Subdireccio´n General de
Evaluacion y Fomento de la Investigacin PS09/02116.
References
1. Treatment-resistant depression: no panacea, many uncertainties. Adverse
effects are a major factor in treatment choice. Prescrire International
2011;20:128–33.
2. Alonso-Vanegas MA, Austria-Velasquez J, Lopez-Gomez M, Brust-Mascher E.
Chronic intermittent vagal nerve stimulation in the treatment of refractory
epilepsy: experience in Mexico with 35 cases. Cirugia y Cirujanos 2010;78:15–
23. 24.
3. Amar AP. Vagus nerve stimulation for the treatment of intractable epilepsy.
Expert Review of Neurotherapeutics 2007;7:1763–73.
4. Amar AP, Apuzzo ML. Vagus nerve stimulation therapy for patients with
persistent seizures after epilepsy surgery. Stereotactic and Functional Neurosur-
gery 2003;80:9–13.
5. Amar AP, Apuzzo ML, Liu CY. Vagus nerve stimulation therapy after failed
cranial surgery for intractable epilepsy: results from the vagus nerve stimula-
tion therapy patient outcome registry. Neurosurgery 2008;62(Suppl. 2):506–13.
6. Bagary M. Epilepsy, consciousness and neurostimulation. Behavioural Neurology
2011;24:75–81.
7. Bao M, Zhou J, Luan GM. Treatment of drug-resistant epilepsy with vagus nerve
stimulation—review of 45 cases. Chinese Medical Journal 2011;124:4184–8.
8. Ben-Menachem E, Manon-Espaillat R, Ristanovic R, Wilder BJ, Stefan H, Mirza
W, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A
controlled study of effect on seizures. First International Vagus Nerve Stimula-
tion Study Group. Epilepsia 1994;35:616–26.
9. Bhattacharya SK, Das BP, Rauniar GP, Sangraula H. Vagus nerve stimulation: a
novel approach for prevention and control of refractory seizures. Kathmandu
University Medical Journal (KUMJ) 2007;5:261–3.
10. Bunch S, DeGiorgio CM, Krahl S, Britton J, Green P, Lancman M, et al. Vagus
nerve stimulation for epilepsy: is output current correlated with acute re-
sponse? Acta Neurologica Scandinavica 2007;116:217–20.
11. Callaghan B, Schlesinger M, Rodemer W, Pollard J, Hesdorffer D, Allen Hauser W,
et al. Remission and relapse in a drug-resistant epilepsy population followed
prospectively. Epilepsia 2011;52:619–26.
12. Casazza M, Avanzini G, Ferroli P, Villani F, Broggi G. Vagal nerve stimulation:
relationship between outcome and electroclinical seizure pattern. Seizure
2006;15:198–207.
13. Cersosimo RO, Bartuluchi M, De Los Santos C, Bonvehi I, Pomata H, Caraballo RH.
Vagus nerve stimulation: effectiveness and tolerability in patients with epilep-
tic encephalopathies. Childs Nervous System 2011;27:787–92.14. Cersosimo RO, Bartuluchi M, Fortini S, Soraru A, Pomata H, Caraballo RH. Vagus
nerve stimulation: effectiveness and tolerability in 64 paediatric patients with
refractory epilepsies. Epileptic Disorders 2011;13:382–8.
15. Connor Jr DE, Nixon M, Nanda A, Guthikonda B. Vagal nerve stimulation for the
treatment of medically refractory epilepsy: a review of the current literature.
Neurosurgical Focus 2012;32:E12.
16. De Herdt V, Boon P, Ceulemans B, Hauman H, Lagae L, Legros B, et al. Vagus
nerve stimulation for refractory epilepsy: a Belgian multicenter study. European
Journal of Paediatric Neurology 2007;11:261–9.
17. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B,
et al. Prospective long-term study of vagus nerve stimulation for the treatment
of refractory seizures. Epilepsia 2000;41:1195–200.
18. DeGiorgio CM, Thompson J, Lewis P, Arrambide S, Naritoku D, Handforth A,
et al. Vagus nerve stimulation: analysis of device parameters in 154 patients
during the long-term XE5 study. Epilepsia 2001;42:1017–20.
19. Elliott RE, Morsi A, Kalhorn SP, Marcus J, Sellin J, Kang M, et al. Vagus nerve
stimulation in 436 consecutive patients with treatment-resistant epilepsy:
long-term outcomes and predictors of response. Epilepsy & Behavior
2011;20:57–63.
20. Englot DJ, Chang EF, Auguste KI. Efﬁcacy of vagus nerve stimulation for epilepsy
by patient age, epilepsy duration, and seizure type. Neurosurgery Clinics of North
America 2011;22:443–8. v.
21. Fisher RS. Therapeutic devices for epilepsy. Annals of Neurology 2012;71:
157–68.
22. Garcia-March G, Sanchez-Ledesma MJ, Broseta J. Vagus nerve stimulation for
the treatment of refractory epilepsy. State of the art. Neurocirugia (Astur)
2008;19:416–26.
23. Garcı´a-Navarrete E, Garcı´a MR, Sola RG MN. Vagus nerve stimulation (VNS)
therapy for the treatment of pharmacoresistant epilepsy: the Spanish experi-
ence. Epilepsia 2007;48(Suppl. 6):127.
24. Hauser WA. The natural history of drug resistant epilepsy: epidemiologic
considerations. Epilepsy Research Supplement 1992;5:25–8.
25. Hui AC, Lam JM, Wong KS, Kay R, Poon WS. Vagus nerve stimulation for
refractory epilepsy: long term efﬁcacy and side-effects. Chinese Medical Journal
2004;117:58–61.
26. Janszky J, Hoppe M, Behne F, Tuxhorn I, Pannek HW, Ebner A. Vagus nerve
stimulation: predictors of seizure freedom. Journal of Neurology Neurosurgery
and Psychiatry 2005;76:384–9.
27. Jaseja H. Vagal nerve stimulation: exploring its efﬁcacy and success for an
improved prognosis and quality of life in cerebral palsy patients. Clinical
Neurology and Neurosurgery 2008;110:755–62.
28. Karceski S. Vagus nerve stimulation and Lennox-Gastaut syndrome: a review of
the literature and data from the VNS patient registry. CNS Spectrums
2001;6:766–70.
29. Kuschyk J, Borggrefe M. Vagus stimulation. Mechanisms and current clinical
importance in heart failure. Herzschrittmachertherapie & Elektrophysiologie
2011;22:21–6.
30. Labar D. Vagus nerve stimulation for 1 year in 269 patients on unchanged
antiepileptic drugs. Seizure 2004;13:392–8.
31. Magdaleno-Madrigal VM. Electrical stimulation of the vagal nerve: from ex-
perimental to clinical aspects. Revista de Neurologia 2004;39:971–7.
32. Majkowska-Zwolinska B, Zwolinski P, Roszkowski M, Drabik K. Long-term
results of vagus nerve stimulation in children and adolescents with drug-
resistant epilepsy. Child’s Nervous System 2012;28(4):621–8.
33. Majoie HJ, Berfelo MW, Aldenkamp AP, Evers SM, Kessels AG, Renier WO. Vagus
nerve stimulation in children with therapy-resistant epilepsy diagnosed as
Lennox-Gastaut syndrome: clinical results, neuropsychological effects, and
cost-effectiveness. Journal of Clinical Neurophysiology 2001;18:419–28.
34. Manta S, Dong J, Debonnel G, Blier P. Optimization of vagus nerve stimulation
parameters using the ﬁring activity of serotonin neurons in the rat dorsal raphe.
European Neuropsychopharmacology 2009;19:250–5.
35. Martin JL, Martin-Sanchez E. Systematic review and meta-analysis of vagus
nerve stimulation in the treatment of depression: variable results based on
study designs. European Psychiatry 2012;27:147–55.
36. Muller K, Fabo D, Entz L, Kelemen A, Halasz P, Rasonyi G, et al. Outcome of vagus
nerve stimulation for epilepsy in Budapest. Epilepsia 2010;51(Suppl. 3):98–101.
37. Navas M, Navarrete EG, Pascual JM, Carrasco R, Nunez JA, Shakur SF, et al.
Treatment of refractory epilepsy in adult patients with right-sided vagus nerve
stimulation. Epilepsy Research 2010;90:1–7.
38. Neligan A, Bell GS, Elsayed M, Sander JW, Shorvon SD. Treatment changes in a
cohort of people with apparently drug-resistant epilepsy: an extended follow-
up. Journal of Neurology Neurosurgery and Psychiatry 2012;83:810–3.
39. Pastor J, Hernando-Requejo V, Dominguez-Gadea L, de Llano I, Meilan-Paz ML,
Martinez-Chacon JL, et al. Impact of experience on improving the surgical
outcome in temporal lobe epilepsy. Revista de Neurologia 2005;41:709–16.
40. Patwardhan RV, Dellabadia Jr J, Rashidi M, Grier L, Nanda A. Control of refractory
status epilepticus precipitated by anticonvulsant withdrawal using left vagal
nerve stimulation: a case report. Surgical Neurology 2005;64:170–3.
41. Polkey CE. Clinical outcome of epilepsy surgery. Current Opinion in Neurology
2004;17:173–8.
42. Renfroe JB, Wheless JW. Earlier use of adjunctive vagus nerve stimulation
therapy for refractory epilepsy. Neurology 2002;59:S26–30.
43. Rizvi SJ, Donovan M, Giacobbe P, Placenza F, Rotzinger S, Kennedy SH. Neuro-
stimulation therapies for treatment resistant depression: a focus on vagus
nerve stimulation and deep brain stimulation. International Review of Psychiatry
2011;23:424–36.
E. Garcı´a-Navarrete et al. / Seizure 22 (2013) 9–13 1344. Scherrmann J, Hoppe C, Kral T, Schramm J, Elger CE. Vagus nerve stimulation:
clinical experience in a large patient series. Journal of Clinical Neurophysiology
2001;18:408–14.
45. Shahwan A, Bailey C, Maxiner W, Harvey AS. Vagus nerve stimulation for
refractory epilepsy in children: more to VNS than seizure frequency reduction.
Epilepsia 2009;50:1220–8.
46. Skarpaas TL, Morrell MJ. Intracranial stimulation therapy for epilepsy. Neu-
rotherapeutics 2009;6:238–43.
47. Sola RG, Hernando-Requejo V, Pastor J, Garcia-Navarrete E, DeFelipe J, Alijarde
MT, et al. Pharmacoresistant temporal-lobe epilepsy. Exploration with foramen
ovale electrodes and surgical outcomes. Revista de Neurologia 2005;41:4–16.
48. Spanaki MV, Allen LS, Mueller WM, Morris 3rd GL. Vagus nerve stimulation
therapy: 5-year or greater outcome at a university-based epilepsy center.
Seizure 2004;13:587–90.
49. Tanganelli P, Ferrero S, Colotto P, Regesta G. Vagus nerve stimulation for
treatment of medically intractable seizures. Evaluation of long-term outcome.
Clinical Neurology and Neurosurgery 2002;105:9–13.
50. Torres CV, Lozano AM. Deep brain stimulation in the treatment of therapy-
refractory depression. Revista de Neurologia 2008;47:477–82.51. Torres CV, Pastor J, Navarrete EG, Sola RG. Thalamic deep brain stimulation for
refractory epilepsy. Revista de Neurologia 2011;53:99–106.
52. Tran Y, Shah AK, Mittal S. Lead breakage and vocal cord paralysis following
blunt neck trauma in a patient with vagal nerve stimulator. Journal of the
Neurological Sciences 2011;304:132–5.
53. Uthman BM, Reichl AM, Dean JC, Eisenschenk S, Gilmore R, Reid S, et al.
Effectiveness of vagus nerve stimulation in epilepsy patients: a 12-year obser-
vation. Neurology 2004;63:1124–6.
54. Wozniak SE, Thompson EM, Selden NR. Vagal nerve stimulator infection: a lead-
salvage protocol. Journal of Neurosurgery Pediatrics 2011;7:671–5.
55. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of
seizure remission in an adult population with refractory epilepsy. Annals of
Neurology 2007;62:382–9.
56. Kwan P, Brodie MJ. Early identiﬁcation of refractory epilepsy. New England
Journal of Medicine 2000;342:314–9.
57. Kwan P, Brodie MJ. Epilepsy after the ﬁrst drug fails: substitution or add-on?
Seizure 2000;9:464–8.
58. Luciano AL, Shorvon SD. Results of treatment changes in patients with appar-
ently drug-resistant chronic epilepsy. Annals of Neurology 2007;62:375–81.
